Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoCCS feasibility study of neoadjuvant docetaxel + cisplatin + capecitabine before surgery in resectable gastric cancer
NL-OMON31603Phase 2Recruiting
- Sponsor
- dr K. Bosscha, surgeon dr J.F.M. Pruijt, oncologist drs A.E. Dassen, resident in training for surgery
- Start
- Jun 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by dr K. Bosscha, surgeon dr J.F.M. Pruijt, oncologist drs A.E. Dassen, resident in training for surgery. Primary endpoints: Feasibility and toxicity/safety of neoadjuvant chemotherapy, Radiologic tumor response and 2 more. Started Jun 2008; status: recruiting.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON31603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31603.